全文获取类型
收费全文 | 3279篇 |
免费 | 302篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 27篇 |
儿科学 | 78篇 |
妇产科学 | 48篇 |
基础医学 | 454篇 |
口腔科学 | 70篇 |
临床医学 | 262篇 |
内科学 | 590篇 |
皮肤病学 | 456篇 |
神经病学 | 185篇 |
特种医学 | 163篇 |
外科学 | 428篇 |
综合类 | 35篇 |
预防医学 | 227篇 |
眼科学 | 25篇 |
药学 | 210篇 |
中国医学 | 5篇 |
肿瘤学 | 340篇 |
出版年
2023年 | 21篇 |
2022年 | 30篇 |
2021年 | 66篇 |
2020年 | 39篇 |
2019年 | 75篇 |
2018年 | 81篇 |
2017年 | 67篇 |
2016年 | 80篇 |
2015年 | 83篇 |
2014年 | 118篇 |
2013年 | 151篇 |
2012年 | 187篇 |
2011年 | 210篇 |
2010年 | 133篇 |
2009年 | 118篇 |
2008年 | 141篇 |
2007年 | 138篇 |
2006年 | 143篇 |
2005年 | 124篇 |
2004年 | 109篇 |
2003年 | 113篇 |
2002年 | 82篇 |
2001年 | 77篇 |
2000年 | 78篇 |
1999年 | 101篇 |
1998年 | 72篇 |
1997年 | 47篇 |
1996年 | 38篇 |
1995年 | 27篇 |
1994年 | 31篇 |
1993年 | 26篇 |
1992年 | 45篇 |
1991年 | 53篇 |
1990年 | 55篇 |
1989年 | 74篇 |
1988年 | 59篇 |
1987年 | 48篇 |
1986年 | 32篇 |
1985年 | 40篇 |
1984年 | 35篇 |
1983年 | 31篇 |
1982年 | 26篇 |
1980年 | 23篇 |
1979年 | 24篇 |
1978年 | 27篇 |
1977年 | 17篇 |
1975年 | 21篇 |
1974年 | 26篇 |
1973年 | 22篇 |
1970年 | 16篇 |
排序方式: 共有3603条查询结果,搜索用时 15 毫秒
71.
72.
73.
T. F. Aarre A. A. Dahl J. B. Johansen I. Kjønniksen D. Neckelmann 《Nordic journal of psychiatry》2013,67(3):227-232
Repetitive transcranial magnetic stimulation (rTMS) is a novel treatment in psychiatry. We reviewed all published evidence on the efficacy of this treatment option in depressive disorders. An extensive electronic and manual search for eligible research reports identified only 12 studies that met the predetermined criteria for inclusion. rTMS was administered differently in most studies, and patient characteristics varied widely. A formal meta-analysis of the studies was thus not possible. Instead, we conducted a qualitative evaluation of the included studies. The antidepressive efficacy was not consistent, and where efficacy was demonstrated, it was modest in most studies. Some patients had good but transient responses to rTMS. Treatment gains were not maintained beyond the treatment period. Comparisons with electroconvulsive therapy (ECT) indicated the superiority of ECT. More, larger and more carefully designed studies are needed to demonstrate convincingly a clinically relevant effect of rTMS. We conclude that there is insufficient evidence for rTMS as a valid treatment for depression at present. 相似文献
74.
75.
Johansen K Hedlund KO Zweygberg-Wirgart B Bennet R 《Scandinavian journal of infectious diseases》2008,40(11-12):958-964
The aim of this retrospective observational study was to evaluate age, length of hospital stay and development of complications in children hospitalized with community- or nosocomially- acquired rotavirus gastroenteritis (RV GE). In total, medical records of 984 children with RV GE were analysed retrospectively. The median age was 13.8 months (3 weeks to 99 months) in children with community acquired RV GE (n=723) and 9.0 months (range 3 weeks to 82 months) in children with nosocomially acquired RV GE (n=261). During this 11-y surveillance, only 2 children were admitted twice for a RV GE, suggesting development of subsequent protective immunity against severe rotavirus gastroenteritis after the first episode. Complications occurred in 16.5% of the children with community acquired RV GE and only in 1.9% of the nosocomially acquired RV GE. Identified complications in children with community acquired RV GE were: severe dehydration resulting in intensive care (1.7%), death (0.1%), hypertonic dehydration (9.1%), seizures (4.0%) and encephalitis with abnormal EEG (1.7%). The median age of children in need of intensive care was 9.1 months and in those developing hypertonic dehydration 10.8 months, both significantly lower than in children with no complications (p<0.05). Interestingly, the age of children developing seizures and signs of encephalitis was significantly higher than in children with no complications (p<0.01). 相似文献
76.
Decreased expression of phospholipase C-beta 2 isozyme in human platelets with impaired function 总被引:4,自引:4,他引:4
Platelets from a patient with a mild inherited bleeding disorder and abnormal platelet aggregation and secretion show reduced generation of inositol 1,4,5-trisphosphate, mobilization of intracellular Ca2+, and phosphorylation of pleckstrin in response to several G protein mediated agonists, suggesting a possible defect at the level of phospholipase C (PLC) activation (see accompanying report). A procedure was developed that allows quantitation of platelet PLC isozymes. After fractionation of platelet extracts by high-performance liquid chromatography, 7 out of 10 known PLC isoforms were detected by immunoblot analysis. The amount of these isoforms in normal platelets decreased in the order PLC- gamma 2 > PLC-beta 2 > PLC-beta 3 > PLC-beta 1 > PLC-gamma 1 > PLC- delta 1 > PLC-beta 4. Compared with normal platelets, platelets from the patient contained approximately one-third the amount of PLC-beta 2, whereas PLC-beta 4 was increased threefold. These results suggest that the impaired platelet function in the patient in response to multiple G protein mediated agonists is attributable to a deficiency of PLC-beta 2. They document for the first time a specific PLC isozyme deficiency in human platelets and provide an unique opportunity to understand the role of different PLC isozymes in normal platelet function. 相似文献
77.
Possible effect of secretor locus on plasma concentration of factor VIII and von Willebrand factor 总被引:2,自引:1,他引:2
A significant fraction (30%) of the genetically determined variance in plasma concentration of the von Willebrand factor antigen (vWf:Ag) has been shown to be related to ABH determinants. Individuals with blood group O, who have the highest amounts of blood group H substance, have the lowest concentration of vWf:Ag. The Lewis substances, Le(a) and Le(b), are biochemically closely related to the ABH substances as both can be produced from the same precursor substance. We studied the effect of the presence of the Lewis antigens on the plasma concentration of vWf:Ag and factor VIII antigen (VIII:Ag) in 323 individuals of different ABO groups from a series of twins and in 58 blood donors of blood group O. Among persons belonging to blood group O, those with the Le(a) antigen had a higher concentration of both vWf:Ag and VIII:Ag than individuals lacking Le(a). Le(a+b-) people are nonsecretors and Le(a-b+) people are secretors of ABH substance. Thus, the lowest concentration of vWf:Ag and VIII:Ag was found in group O secretors. The effect is most likely due to an effect of the secretor locus. This finding may be of importance for the detection of carriers of hemophilia A and for the diagnosis of type I von Willebrand disease. 相似文献
78.
Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8‐GP) and development of a human pharmacokinetic prediction model
下载免费PDF全文
![点击此处可从《Journal of thrombosis and haemostasis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
F. Rode K. Almholt M. Petersen M. Kreilgaard M. Kjalke D. M. Karpf A. V. Groth P. B. Johansen L. F. Larsen M. Loftager J. Haaning 《Journal of thrombosis and haemostasis》2018,16(6):1141-1152
Essentials
- N8‐GP is an extended half‐life recombinant factor VIII (FVIII) for the treatment of hemophilia A.
- Subcutaneous (SC) FVIII dosing might reduce the treatment burden of prophylaxis.
- SC N8‐GP has a favorable PK profile in animal models and disappears from skin injection sites.
- Combined animal (SC) and clinical (IV) data suggest that daily SC dosing may provide prophylaxis.
Summary
Background
N8‐GP is an extended half‐life recombinant factor VIII (FVIII) for the treatment of hemophilia A. Subcutaneous administration of FVIII may reduce the treatment burden of prophylaxis; however, standard FVIII products have low bioavailability after subcutaneous dosing in animals.Objective
To evaluate the pharmacokinetics, effectiveness and local distribution of subcutaneously administered N8‐GP in preclinical models and predict the human pharmacokinetic (PK) profile.Methods
The pharmacokinetics of subcutaneously administered N8‐GP were evaluated in FVIII knockout (F8‐KO) mice and cynomolgus monkeys; a human PK prediction model in hemophilia A patients was developed. The hemostatic effect was evaluated in a tail vein bleeding model in F8‐KO mice. The injection‐site distribution and absorption of subcutaneously administered N8‐GP were assessed in F8‐KO mice by the use of temporal fluorescence imaging and immunohistochemistry.Results
Subcutaneously administered N8‐GP had a bioavailability, a first‐order absorption rate and a half‐life, respectively, of 24%, 0.094 h?1 and 14 h in F8‐KO mice, and 26%, 0.33 h?1 and 15 h in cynomolgus monkeys. A dose‐dependent effect of subcutaneously administered N8‐GP on blood loss was observed in mice. A minimal amount of N8‐GP was detected at the injection site 48–72 h after single or multiple dose(s) in F8‐KO mice. Subcutaneously administered N8‐GP was localized to the skin around the injection site, with time‐dependent disappearance from the depot. PK modeling predicted that subcutaneously administered N8‐GP at a daily dose of 12.5 IU kg?1 will provide FVIII trough levels of 2.5–10% in 95% of patients with severe hemophilia A.Conclusions
Subcutaneously administered N8‐GP may provide effective hemophilia A prophylaxis. A phase I clinical trial is underway to investigate this possibility.79.